Comparative analysis of triplex nucleic acid test assays in United States blood donors

Transfusion

Volumn 53, Issue 10 PART 2, 2013, Pages 2525-2537

  Stramer, Susan L ^a,b,c,d,e   Krysztof, David E ^a,b,c,d,e   Brodsky, Jaye P ^a,b,c,d,e   Fickett, Tracy A ^a,b,c,d,e   Reynolds, Benjamin ^a,b,c,d,e   Dodd, Roger Y ^a,b,c,d,e   Kleinman, Steven H ^a,b,c,d,e  

^a AMERICAN RED CROSS   (United States)

^b Quality Analytics   (United States)

^c CREATIVE TESTING SOLUTIONS   (United States)

^d HOLLAND LABORATORY   (United States)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

ARTICLE; BLOOD; BLOOD DONOR; BLOOD SAMPLING; COMPARATIVE STUDY; EPIDEMIOLOGY; EVALUATION STUDY; GENETICS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; ISOLATION AND PURIFICATION; METHODOLOGY; NUCLEIC ACID AMPLIFICATION; SENSITIVITY AND SPECIFICITY; SEROLOGY; UNITED STATES; HEPACIVIRUS; HIV INFECTIONS; PROCEDURES;

BLOOD DONORS; BLOOD SPECIMEN COLLECTION; HEPACIVIRUS; HEPATITIS ANTIBODIES; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS C; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; NUCLEIC ACID AMPLIFICATION TECHNIQUES; SENSITIVITY AND SPECIFICITY; SEROEPIDEMIOLOGIC STUDIES; SEROLOGIC TESTS; UNITED STATES;

EID: 84891671422     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12178     Document Type: Article

References (37)

1. Roche Molecular Systems, Inc. cobas® TaqScreen MPX Test for use on the cobas s 201 System product insert: 1636, Rev4. 2009. Indianapolis, IN, USA.
2. Gen-Probe, Incorporated. Procleix® Ultrio® Assay product insert: 502165, Rev. A. 2011. San Diego, CA, USA.
3. Gen-Probe, Incorporated. Procleix® Ultrio® Plus Assay product insert: 502932, Rev. 7. 2012. San Diego, CA, USA.
4. Roth WR, Busch MP, Schuller A, Ismay S, Cheng A, Seed CR, Jungbauer C, Minsk PM, Sondag-Thull D, Wendel S, Levi JE, Fearon M, Delage G, Xie Y, Jukic' I, Turek P, Ullum H, Tefanova V, Tilk M, Reimal R, Castren J, Naukkarinen M, Assal A, Jork C, Reesink HW et al. International survey on NAT testing of blood donations: expanding implementation and yield from 1999 to 2009. Vox Sang 2012;102:82-90.
5. Assal A, Barlet V, Deschaseaux M, Dupont I, Gallian P, Guitton C, Morel P, van Drimmelen H, David B, Lelie N, DeMicco P. Sensitivity of two hepatitis B virus, hepatitis C virus (HCV), and human immunodeficiency virus (HIV) nucleic acid test systems relative to hepatitis B surface antigen, anti-HCV, anti-HIV, and p24/anti-HIV combination assays in seroconversion panels. Transfusion 2009;49: 301-10.
6. Margaritis AR, Brown SM, Seed CR, Kiely P, D'Agostino B, Keller AJ. Comparison of two automated nucleic acid testing systems for simultaneous detection of human immunodeficiency virus and hepatitis C virus RNA and hepatitis B virus DNA. Transfusion 2007;47:1783-93.
7. Phikulsod S, Oota S, Tirawatnapong T, Sakuldamrongpanich T, Chalermchan W, Louisirirotchanakul S, Tanprasert S, Chongkolwatana V, Kitpoka P, Praphan Phanuphak P, Wasi C, Nuchprayoon C; TheWorking Group for NAT Study in Thai Blood Donations. One-year experience of nucleic acid technology testing for human immunodeficiency virus type 1, hepatitis C virus, and hepatitis B virus in Thai blood donations. Transfusion 2009;49:1126-35.
8. Louisirirotchanakul S, Oota S, Khuponsarb K, Chalernchan W, Phikulsod S, Chongkolwatana V, Sakuldamrongpanish T, Kitpoka P, Chielsilp P, Tirawatnapong T, Wasi C; the Working Group for NAT Study in Thai Blood Donations. Occult hepatitis B virus infection in Thai blood donors. Transfusion 2011;51:1532-40.
9. Stramer SL, Krysztof DE, Brodsky JP, Fickett TA, Reynolds B, Phikulsod S, Oota S, Lin M, Saldanha J, Kleinman SH. Sensitivity comparison of two Food and Drug Administration-licensed, triplex nucleic acid test automated assays for hepatitis B virus DNA detection and associated projections of United States yield. Transfusion 2011; 51:2012-22.
10. Stramer SL, Wend U, Candotti D, Foster GA, Hollinger FB, Dodd RY, Allain JP, Gerlich W. Nucleic acid testing to detect HBV infection in blood donors. N Engl J Med 2011; 364:236-47.
11. Stramer SL, Glynn SA, Kleinman SH, Wright DJ, Dodd RY, Busch MP; National Heart, Lung, and Blood Institute Nucleic Acid Test Study Group. Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. N Engl J Med 2004;351: 760-8.
12. Stramer SL, Zou D, Notari EP, Foster GA, Krysztof DE, Musavi F, Dodd RY. Blood donation screening for hepatitis B virus markers in the era of nucleic acid testing: are all tests of value? Transfusion 2012;52:440-6.
13. Zou S, Stramer SL, Notari EP, Kuhns MC, Krysztof D, Musavi F, Fang CT, Dodd RY. Current incidence and residual risk of hepatitis B infection among blood donors in the United States. Transfusion 2009;49:1609-20.
14. Katz L, Strong DM, Tegtmeier G, Stramer S. Performance of an algorithm for the reentry of volunteer blood donors deferred due to false-positive test results for antibody to hepatitis B core antigen. Transfusion 2008;48:2315-22.
15. McNemar Q. Note on the sampling error of the difference between correlated proportions or percentages. Psychometrika 1947;12:153-7.
16. Durkalski VL, Palesch YY, Lipsitz SR, Rust PF. Analysis of clustered matched-pair data. Stat Med 2003;22:2417-28.
17. US Food and Drug Administration. Guidance for industry: nucleic acid testing (NAT) for human immunodeficiency virus type 1 (HIV-1) and hepatitis C virus (HCV): testing, product disposition, and donor deferral and reentry. May 2010 [cited 2012 Dec 2]. Available from: URL: http://www.fda.gov/ BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/ default.htm
18. US Food and Drug Administration. Guidance for industry: use of nucleic acid tests on pooled and individual samples from donors of whole blood and blood components, including source plasma, to reduce the risk of transmission of hepatitis B virus. Oct 2012. [cited 2012 Dec 2]. Available from: URL: http://www.fda.gov/BiologicsBloodVaccines/ GuidanceComplianceRegulatoryInformation/Guidances/ default.htm
19. Busch MP, Glynn SA, Stramer SL, Strong DM, Caglioti S, Wright DJ, Pappalardo B, Kleinman SH; NHLBI-REDS NAT Study Group. A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors. Transfusion 2005;45: 254-64.
20. Busch MP, Glynn SA, Wright DJ, Hirschkorn D, Laycock ME, McAuley J, Tu Y, Giachetti C, Gallarda J, Heitman J, Kleinman SH for the National Heart, Lung, and Blood Institute Nucleic Acid Test Study Group. Relative sensitivities of licensed nucleic acid amplification tests for detection of viremia in early human immunodeficiency virus and hepatitis C virus infection. Transfusion 2005;45:1853-63.
21. Assal A, Barlet V, Deschaseaux M, Dupont I, Gallian P, Guitton C, Morel P, David B, De Micco P. Comparison of the analytical and operational performance of two viral nucleic acid test blood screening systems: Procleix Tigris and cobas s 201. Transfusion 2009;49:289-300.
22. Allain JP. Occult hepatitis B virus infection: implications in transfusion. Vox Sang 2004;86:83-91.
23. Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DC, Colombo M, Carxi A, Donato F, Ferrari C, Gaeta GB, Gerlich WH, Levrero M, Locarnini S, Michalak T, Mondell MU, Pawlotsky JM, Pollicino T, Prati D, Puoti M, Samuel D, Shouval D, Smedile A, Squadrito G, Trepo C, Zoulim F et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 2008;49:652-7.
24. Deeks SG, Walker BD. Human immunodeficiency virus controllers: mechanisms of durable viral control in the absence of antiretroviral therapy. Immunity 2007;27:406-16
25. Hatano H, Delwart EL, Norris PJ, Lee TH, Dunn-Williams J, Hunt PW, Hoh R, Stramer SL, Linnen JM, McCune JM, Martin JN, Busch MP, Deeks SG. Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy. J Virol 2009;83:329-35.
26. Vermeulen M, Dickens C, Lelie N, Walker E, Coleman C, Keyter M, Reddy R, Crookes R, Kramvis A. Hepatitis B virus transmission by blood transfusion during 4 years of individual-donation nucleic acid testing in South Africa: estimated and observed window period risk. Transfusion 2012;52:88-92.
27. Hollinger FB. Hepatitis B virus infection and transfusion medicine: science and the occult. Transfusion 2008;48: 1001-26.
28. Vermeulen M, Lelie N, Sykes W, Crookes R, Swanevelder J, Gaggia L, Le Roux M, Kuun E, Gulube S, Reddy R. Impact of individual-donation nucleic acid testing on risk of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission by blood transfusion in South Africa. Transfusion 2009;49:1115-25.
29. Glynn SA, Wright DJ, Kleinman SH, Hirschkorn D, Tu Y, Hildebrant C, Smith R, Giachetti C, Gallarda J, Busch MP. Dynamics of viremia in early hepatitis C virus infection. Transfusion 2005;45:994-1002.
30. Dodd RY, Notari EP, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window period risk in the American Red Cross blood donor population. Transfusion 2002;42:975-9.
31. Zou S, Dorsey KA, Notari EP, Foster GA, Krysztof DE, Musavi F, Dodd RY, Stramer SL. Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing. Transfusion 2010;50:1495-504.
32. Kleinman SH, Stramer SL, Brodsky JP, Caglioti S, Busch MP. Integration of nucleic acid amplification test results into hepatitis C virus supplemental serologic testing algorithms: implications for donor counseling and revision of existing algorithms. Transfusion 2006;46:695-702.
33. Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N, Nolt K, Nelson KF, Strathdee SA, Johnson L, Laeyendecker O, Boitnott J, Wilson LE, Vlahov D. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000;284:450-6.
34. Seeff LB, Hollinger FB, Alter HJ, Wright EC, Cain CM, Buskell ZJ, Ishak KG, Ider FL, Toro D, Samanta A, Koretz RL, Perrillo RP, Goodman ZD, Knodell RG, Gitnick G, Morgan TR, Schiff ER, Lasky S, Stevens C, Vlahcevic RZ, Weinshel E, Tanwandee T, Lin HJ, Barbosa L. Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: a National Heart, Lung, and Blood Institute collaborative study. Hepatology 2001;33: 455-63.
35. Jauncey M, Micallef JM, Gilmour S, Amin J, White PA, Rawlinson W, Kaldor JM, van Beek I, Dore GJ. Clearance of hepatitis C virus after newly acquired infection in injection drug users. J Infect Dis 2004;190:1270-4.
36. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39:1147-71.
37. Laperche S, Morel P, Deschaseaux M, Bouchardeau F, Alimardani G, Guillaume N, Rouger P, Lefrère JJ. HIV antibody screening remains indispensable for ensuring viral safety of blood components despite NAT implementation. Transfusion 2003;43:1428-32.